Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
The product is being launched in August 2023
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
The company has reported total income of Rs. 1248.51 crores during the period ended June 30, 2023
The company has secured 506 marketing approvals for its oncology products across 76 countries.
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
Subscribe To Our Newsletter & Stay Updated